Vertex Pharmaceuticals Inc Earnings
The next earnings date for Vertex Pharmaceuticals Inc has not yet been scheduled.
Analyst Estimates of Vertex Pharmaceuticals Inc Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Vertex Pharmaceuticals Inc Earnings: Historical
| 08/03/2026 | After Market | $4.20 | 1.20% |
| 05/04/2026 | After Market | $4.47 | 3.81% |
| 02/12/2026 | After Market | $5.03 | -2.33% |
| 11/03/2025 | After Market | $4.80 | 4.80% |
| 08/04/2025 | After Market | $4.52 | 6.35% |
| 05/05/2025 | After Market | $4.06 | -5.36% |
| 02/10/2025 | After Market | $3.98 | -1.00% |
| 11/04/2024 | After Market | $4.38 | 6.05% |
| 08/01/2024 | After Market | $-12.83 | -9.19% |
| 05/06/2024 | After Market | $4.76 | 17.24% |
More About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
“Vertex Pharmaceuticals Inc Earnings” Can Refer to the Vertex Pharmaceuticals Inc Earnings Date
Some people say “Vertex Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Vertex Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Vertex Pharmaceuticals Inc Stock on the Earnings Date
If you own Vertex Pharmaceuticals Inc stock (VRTX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Vertex Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Vertex Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Owning Vertex Pharmaceuticals Inc Options on the Earnings Date
If you own Vertex Pharmaceuticals Inc options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
In addition, the extrinsic values of Vertex Pharmaceuticals Inc options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own Vertex Pharmaceuticals Inc options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.
This makes sense considering that prices are often more volatile on earnings dates for Vertex Pharmaceuticals Inc. That potential volatility is a key factor that affects the premium cost of owning options.
Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of Vertex Pharmaceuticals Inc options often go down. This is sometimes referred to as volatility crush.
Learning More Vertex Pharmaceuticals Inc Earnings
You can contact us any time if you would like to ask questions about Vertex Pharmaceuticals Inc earnings or anything else related to the stock market.